Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Circulating Tumor Dna To Monitor Treatment Response And Detect Acquired Resistance In Patients With Metastatic Melanoma, Elin S. Gray, Helen Rizos, Anna L. Reid, Suzanah Boyd, Michelle Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard Scolyer, Kelvin Siew, Chris Lomma, Adam Cooper, Muhammad Khattak, Tarek Meniawy, Georgina Long, Matteo Carlino, Michael Millward, Mel R. Ziman
Circulating Tumor Dna To Monitor Treatment Response And Detect Acquired Resistance In Patients With Metastatic Melanoma, Elin S. Gray, Helen Rizos, Anna L. Reid, Suzanah Boyd, Michelle Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard Scolyer, Kelvin Siew, Chris Lomma, Adam Cooper, Muhammad Khattak, Tarek Meniawy, Georgina Long, Matteo Carlino, Michael Millward, Mel R. Ziman
Research outputs 2014 to 2021
Repeat tumor biopsies to study genomic changes during therapy are difficult, invasive and data are confounded by tumoral heterogeneity. The analysis of circulating tumor DNA (ctDNA) can provide a non-invasive approach to assess prognosis and the genetic evolution of tumors in response to therapy. Mutation-specific droplet digital PCR was used to measure plasma concentrations of oncogenic BRAF and NRAS variants in 48 patients with advanced metastatic melanoma prior to treatment with targeted therapies (vemurafenib, dabrafenib or dabrafenib/trametinib combination) or immunotherapies (ipilimumab, nivolumab or pembrolizumab). Baseline ctDNA levels were evaluated relative to treatment response and progression-free survival (PFS). Tumor-associated ctDNA was …
Integrating Psychosocial Care Into Neuro-Oncology: Challenges And Strategies, Suzanne K. Chambers, L. Grassi, M.K. Hyde, J. Holland, J. Dunn
Integrating Psychosocial Care Into Neuro-Oncology: Challenges And Strategies, Suzanne K. Chambers, L. Grassi, M.K. Hyde, J. Holland, J. Dunn
Research outputs 2014 to 2021
Approximately 256,000 cases of malignant brain and nervous system cancer were diagnosed worldwide during 2012 and 189,000 deaths, with this burden falling more heavily in the developed world. Problematically, research describing the psychosocial needs of people with brain tumors and their carers and the development and evaluation of intervention models has lagged behind that of more common cancers. This may relate, at least in part, to poor survival outcomes and high morbidity associated with this illness, and stigma about this disease. The evidence base for the benefits of psychosocial care in oncology has supported the production of clinical practice guidelines …